Table 5.
Clinical Trials With Bevacizumab in Patients With Malignant Gliomas.
Authors | No. of patients | Radiographic Response Rates (%) | PFS (mo) | OS (mo) |
---|---|---|---|---|
Stark-Vance40 | 21 | 43 | — | — |
Friedman et al.41 | Bev alone: 85 | 28 | 4.2 | 9.2 |
Bev + CPT-11: 82 | 38 | 5.6 | 8.7 | |
Kreisl et al.42 | 48 | 35 | 4.0 | — |
Vredenburgh et al.43 | 35 | 57 | — | — |
Abbreviations: Bev, bevacizumab; CPT, irinotecan; OS, overall survival; PFS, progression-free survival.